GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriter’s Option...
GW Pharma (NASDAQ: GWPH) announced this evening that is has priced a secondary offering at $90, raising $252mm by selling 2.8mm shares. The underwriters include Morgan Stanley, BofA Merrill...
GW Pharmaceuticals Announces Proposed Public Offering of ADSs LONDON, July 12, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing...
It has been a while since my first interview with CannaInsider, and host Matthew Kind invited me for a follow-up. I noted that the huge progress the cannabis industry has made over the past...
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome – Primary endpoint achieved with high statistical significance (p=0.0135) showing that...
GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS) – Orphan Drug Designation Granted from FDA for Epidiolex for the Treatment of IS...
Most investors understand the importance of listening to quarterly conference calls, as companies will often reveal important information in either the prepared remarks or the Q&A that follows that isn’t conveyed...
GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress – Positive Phase 3 Epidiolex pivotal trial in Dravet syndrome – – Initial LGS Phase...
Two months ago, cannabis stocks, as measured by the 420 Investor Cannabis Stock Index, were down in the dumps. At their trough, the index, which currently has 27 members (based...
GW Pharmaceuticals Receives Orphan Drug Designation from FDA for Cannabidiol for the Treatment of Tuberous Sclerosis Complex LONDON, April 21, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP)...
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex LONDON, April 11, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical...
Alan Brochstein, CFA, presented “3 Years Later, Only a Few Cannabis Stocks Appear Capable to Deliver” at the MoneyShow’s Cannabis Investing Virtual Event on March 29th. For those not immersed yet...
Following through with a promise delivered on StockTwits last week, “The Vega Group” has published a negative report on GW Pharma (NASDAQ: GWPH) (LON: GWP). The stock had reacted...
Motley Fool Contributor Todd Campbell, who operates E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors, has been cautious on the prospects for GW Pharma (NASDAQ:...
Bruce Barcott reviewed portions of the impressive intellectual property portfolio of GW Pharma (NASDAQ: GWPH), which the company summarized in its annual filing: Our intellectual property portfolio at September 30,...
GW Pharma is trading near $74 following the issuance of a press release detailing the first of four late-stage clinical trials for its epilepsy drug, Epidiolex. The stock has...
GW Pharma (NASDAQ: GWPH) (LON: GWP) will soon announce the results from the first of four Phase 3 clinical trials for Epidiolex, its antiepileptic drug targeting seizure reduction for patients with...
CFN Media Group published an article about investing in cannabis stocks, suggesting that it remains a “Wild West”. Some of the takeaways: Canada is a safer market in which...
UK-based investment research firm Edison updated its views on GW Pharma (NASDAQ: GWPH) today. Analyst Maxim Jacobs is targeting a price of 587 pence, which, at the current dollar/pound...
New Cannabis Ventures reported yesterday that the Food & Drug Administration (FDA) had issued 8 warning letters to marketers of hemp-derived CBD products, and the FDA actions are sending a chill...
Similar to a year ago, when the Food & Drug Administration (FDA) issued warning letters to six companies, the FDA issued several warning letters to marketers of products with cannabidiol...
GW Pharmaceuticals plc Reports First Quarter 2016 Financial Results and Operational Progress -Three Phase 3 Epidiolex clinical trials fully recruited above target sample size — on track for initial...
The Financial Times shared a great history of the ups and downs of GW Pharma (NASDAQ: GWPH), which will soon report the results of the first of four Phase...
Alan Brochstein published an article on the publicly-traded Canadian cannabis stocks, including Aphria, Aurora Cannabis, Canopy Growth, Emerald Health, Mettrum, OrganiGram, PharmaCan Capital and Supreme Pharma. The article, which is...
GW Pharmaceuticals (NASDAQ: GWPH) reported yesterday that Founder and Chairman Geoffrey Guy has sold about 100K shares, with the majority of the sales taking place on Friday, December 18th. The...
